mp.weixin.qq.com·· 12 hours agoPickScore86
Chia Tai Tianqing's TQB2102 Cuts Progression or Death Risk 71% Versus Chemotherapy in APEX-Breast01 in HER2-Low Advanced Breast Cancer
In brief
Chia Tai Tianqing presented APEX-Breast01 results for TQB2102 at ESMO 2026, showing it significantly improved median progression-free survival (mPFS) over chemotherapy in patients with HER2-low advanced breast cancer. TQB2102, a next-generation HER2 bispecific ADC, achieved an mPFS of 16.4 months versus 5.5 months with chemotherapy, a 71% reduction in the risk of disease progression or death, with treatment-related interstitial lung disease (ILD) occurring in 2.2% of patients.
Why it matters
APEX-Breast01 provides mPFS, progression or death risk, and ILD data for TQB2102 versus chemotherapy, allowing direct comparison of efficacy and safety.
Source: mp.weixin.qq.com · mp.weixin.qq.com